JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

AbCellera Biologics Inc

Cerrado

SectorSalud

4.7 -4.47

Resumen

Variación precio

24h

Actual

Mínimo

4.63

Máximo

4.93

Métricas clave

By Trading Economics

Ingresos

-11M

-46M

Ventas

-815K

4.2M

Margen de beneficio

-1,077.237

Empleados

596

EBITDA

16M

-40M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+103.25% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

854M

1.5B

Apertura anterior

9.17

Cierre anterior

4.7

Noticias sobre sentimiento de mercado

By Acuity

31%

69%

84 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 23:57 UTC

Adquisiciones, fusiones, absorciones

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Adquisiciones, fusiones, absorciones

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Charlas de Mercado

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Charlas de Mercado

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Ganancias

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Charlas de Mercado
Ganancias

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Ganancias

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Ganancias

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Ganancias

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Ganancias

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

103.25% repunte

Estimación a 12 meses

Media 10 USD  103.25%

Máximo 17 USD

Mínimo 5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

84 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.